$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000114420418009768 Filed on February 20, 2018

Income Statement

Concept	2017 Q4	2016 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.010M	$1.040M
YoY Change	-2.88%	10.64%
% of Gross Profit
Research & Development	$1.640M	$1.261M
YoY Change	30.03%	9.41%
% of Gross Profit
Depreciation & Amortization	$166.7K	$162.4K
YoY Change	2.65%	-0.88%
% of Gross Profit
Operating Expenses	$2.394M	$2.298M
YoY Change	4.19%	9.92%
Operating Profit	-$2.394M	-$2.298M
YoY Change	4.19%	9.92%
Interest Expense	$1.060M	$245.0K
YoY Change	332.65%	0.0%
% of Operating Profit
Other Income/Expense, Net	-$403.1K	$751.2K
YoY Change	-153.66%	-209.67%
Pretax Income	-$2.797M	-$1.546M
YoY Change	80.86%	-44.28%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.797M	-$1.546M
YoY Change	80.86%	-44.28%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04	-$0.03
Diluted Earnings Per Share	-$0.04	-$0.03
COMMON SHARES
Basic Shares Outstanding	63.34M shares	58.21M shares
Diluted Shares Outstanding	63.34M shares	58.21M shares

Balance Sheet

Concept	2017 Q4	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.05M	$19.30M
YoY Change	-37.56%	-31.66%
Cash & Equivalents	$12.05M	$19.30M
Short-Term Investments
Other Short-Term Assets	$240.0K	$140.0K
YoY Change	71.43%	27.27%
Inventory
Prepaid Expenses		$139.7K
Receivables
Other Receivables
Total Short-Term Assets	$12.29M	$19.44M
YoY Change	-36.78%	-31.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.03M	$11.46M
YoY Change	-3.75%	-4.51%
Goodwill
YoY Change
Intangibles		$387.3K
YoY Change		-2.09%
Long-Term Investments
YoY Change
Other Assets	$30.00K	$80.00K
YoY Change	-62.5%	-27.27%
Total Long-Term Assets	$11.44M	$11.92M
YoY Change	-4.02%	-4.69%
TOTAL ASSETS
Total Short-Term Assets	$12.29M	$19.44M
Total Long-Term Assets	$11.44M	$11.92M
Total Assets	$23.73M	$31.36M
YoY Change	-24.33%	-23.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.550M	$160.0K
YoY Change	868.75%	-87.6%
Accrued Expenses	$30.00K	$51.59K
YoY Change	-41.85%	309.57%
Deferred Revenue
YoY Change
Short-Term Debt	$5.160M	$5.910M
YoY Change	-12.69%
Long-Term Debt Due		$5.911M
YoY Change
Total Short-Term Liabilities	$6.740M	$6.320M
YoY Change	6.65%	330.93%
LONG-TERM LIABILITIES
Long-Term Debt	$4.730M	$3.520M
YoY Change	34.38%	-55.22%
Other Long-Term Liabilities	$1.070M	$2.380M
YoY Change	-55.04%	-23.96%
Total Long-Term Liabilities	$4.730M	$5.902M
YoY Change	-19.86%	-46.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.740M	$6.320M
Total Long-Term Liabilities	$4.730M	$5.902M
Total Liabilities	$7.810M	$12.22M
YoY Change	-36.08%	-1.98%
SHAREHOLDERS EQUITY
Retained Earnings		-$69.43M
YoY Change		19.34%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.92M	$19.15M
YoY Change
Total Liabilities & Shareholders Equity	$23.73M	$31.36M
YoY Change	-24.34%	-23.22%

Cashflow Statement

Concept	2017 Q4	2016 Q4
OPERATING ACTIVITIES
Net Income	-$2.797M	-$1.546M
YoY Change	80.86%	-44.28%
Depreciation, Depletion And Amortization	$166.7K	$162.4K
YoY Change	2.65%	-0.88%
Cash From Operating Activities	-$1.400M	-$2.620M
YoY Change	-46.56%	114.75%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$60.00K	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities	-1.400M	-2.620M
Cash From Investing Activities	-60.00K	0.000
Cash From Financing Activities
Net Change In Cash	-1.460M	-2.620M
YoY Change	-44.27%	109.6%
FREE CASH FLOW
Cash From Operating Activities	-$1.400M	-$2.620M
Capital Expenditures	-$60.00K	$0.00
Free Cash Flow	-$1.340M	-$2.620M
YoY Change	-48.85%	120.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	95781779	USD
	us-gaap	Depreciation Depreciation	325720	USD
	us-gaap	Depreciation Depreciation	332921	USD
	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	312207	USD
	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	54000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4802449	USD
	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	22500	USD
	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	10174	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	76500	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	76500	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4135	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4135	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1421062	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-79.737	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4836184	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2960521	USD
	us-gaap	Interest Paid Net InterestPaidNet	326667	USD
	us-gaap	Interest Paid Net InterestPaidNet	166667	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24162185	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19301566	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	359214	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	826749	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4607843	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1665151	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	49366	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	92540	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24435	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	10174	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	355335	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	312207	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-28514	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-23375	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-59966	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	29535	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	1134141	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-734830	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-41667	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-83334	USD
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2000-07-25
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6650996	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6696724	shares
CY2017Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7996402	USD
CY2017Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	48486	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5466066	USD
CY2017Q4	us-gaap	Land Land	260000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	383198	USD
CY2013Q3	nnvc	Warrants Issued WarrantsIssued	2945428	shares
CY2014Q1	nnvc	Warrants Issued WarrantsIssued	2479935	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2810071	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2479935	shares
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	nnvc	Obligation To Issue Registered Shares ObligationToIssueRegisteredShares	5163194	USD
CY2017Q2	nnvc	Obligation To Issue Registered Shares ObligationToIssueRegisteredShares	0	USD
CY2017Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1386135	USD
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1261000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2541363	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2713137	USD
CY2017Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1007646	USD
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1036618	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2082864	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2024930	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	2393781	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	2297618	USD
	us-gaap	Operating Expenses OperatingExpenses	4624227	USD
	us-gaap	Operating Expenses OperatingExpenses	4738067	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2393781	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2297618	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4624227	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4738067	USD
CY2017Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1348247	USD
CY2016Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1348247	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q4	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	119863	USD
CY2016Q4	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	423287	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	359214	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	826749	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1421062	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1665151	USD
CY2016Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1407771	USD
CY2017Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1100302	USD
CY2017Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-403113	USD
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	751218	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-178222	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	130224	USD
CY2017Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2796894	USD
CY2016Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1546400	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4802449	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4607843	USD
CY2017Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-1546400	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-2796894	USD
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2017Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63335601	shares
CY2016Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58205494	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63321342	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58192721	shares
CY2017Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63335601	shares
CY2016Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58205494	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63321342	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58192721	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63372681	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63372681	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63306774	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63306774	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Note 1 - Organization and Nature of Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">NanoViricides, Inc. (the “Company”) was incorporated under the laws of the State of Colorado on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> July 25, 2000</font> as <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Edot-com.com, Inc<b>.</b></font> which was organized for the purpose of conducting internet retail sales. On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation. On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired NanoViricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). NanoViricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font> shares of ECMM common stock issued and outstanding. NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s Common Stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of ECMM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV-1 and HSV-2), Influenza and Asian Bird Flu Virus. Under the License Agreements, TheraCour Pharma will receive a royalty upon sale of resulting products from NanoViricides. There is no royalty payable to date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">On February 15, 2010 the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(adjusted for the 3.5 to 1 reverse split)</font> of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only in the event of a “change of control” of the Company, as defined in the designation of Series A Preferred Stock (see Note 2 for further details), into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4	us-gaap	Business Acquisition Name Of Acquired Entity BusinessAcquisitionNameOfAcquiredEntity	Edot-com.com, Inc.
CY2017Q4	us-gaap	Business Acquisition Date Of Acquisition Agreement1 BusinessAcquisitionDateOfAcquisitionAgreement1	2005-05-12
	nnvc	Commonsharesto Beissued Fordebentureinterest CommonsharestoBeissuedFordebentureinterest	60274	USD
	nnvc	Commonsharesto Beissued Fordebentureinterest CommonsharestoBeissuedFordebentureinterest	0	USD
CY2017Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2796894	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1546400	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4802449	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4607843	USD
CY2017Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2016Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.03
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.08
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.08
CY2017Q4	us-gaap	Depreciation Depreciation	166732	USD
CY2016Q4	us-gaap	Depreciation Depreciation	162433	USD
CY2017	nnvc	Net Proceeds From Issuance Of Debt NetProceedsFromIssuanceOfDebt	1968275	USD
CY2017Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	5864337	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-701143	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	5163194	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	7716	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	15432	shares
CY2017Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	19836	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	45063	USD
CY2017Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	24970	USD
CY2016Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	11734	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	49362	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	25911	USD
CY2017Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	60275	USD
CY2016Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	245000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	185274	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	490000	USD
CY2017Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4401	USD
CY2017Q4	nnvc	Net Proceeds From Issuance Of Debt NetProceedsFromIssuanceOfDebt	1968275	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	125000	USD
CY2017	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	150000	shares
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	701143	USD
CY2017Q4	nnvc	Share Price As Per Redemption Agreement SharePriceAsPerRedemptionAgreement	0.0100	pure
CY2017Q4	us-gaap	Share Price SharePrice	0.88
CY2017Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	41143	USD
	nnvc	Obligation To Issue Shares For Series C Debenture Payment ObligationToIssueSharesForSeriesCDebenturePayment	5739337	USD
	nnvc	Obligation To Issue Shares For Series C Debenture Payment ObligationToIssueSharesForSeriesCDebenturePayment	0	USD
	nnvc	Obligation To Issue Shares For Deferred Interest ObligationToIssueSharesForDeferredInterest	125000	USD
CY2017Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5864337	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5300000	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	0	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-246667	USD

Files In Submission

Name	View Source	Status
0001144204-18-009768-index-headers.html	Edgar Link	pending
0001144204-18-009768-index.html	Edgar Link	pending
0001144204-18-009768.txt	Edgar Link	pending
0001144204-18-009768-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nnvc-20171231.xml	Edgar Link	completed
nnvc-20171231.xsd	Edgar Link	pending
nnvc-20171231_cal.xml	Edgar Link	unprocessable
nnvc-20171231_def.xml	Edgar Link	unprocessable
nnvc-20171231_lab.xml	Edgar Link	unprocessable
nnvc-20171231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv485567_10q.htm	Edgar Link	pending
tv485567_ex31-1.htm	Edgar Link	pending
tv485567_ex31-2.htm	Edgar Link	pending
tv485567_ex32-1.htm	Edgar Link	pending
tv485567_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2017 Q4 Form 10-Q Financial Statement

#000114420418009768 Filed on February 20, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2017 Q4 Form 10-Q Financial Statement

#000114420418009768 Filed on February 20, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc